|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
The Therapeutic Proteins Outlook To 2007
This report provides product forecasts to 2007, and defines the driving forces that will impact the therapeutic proteins market, allowing you to determine how the future competitive landscape will affect your company.
Monoclonal Antibody Therapies: Sector Analysis Tool
The monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004. It has the potential to triple in value over the next six years and reach $30.
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain..
The treatment of RA has changed significantly as treatment shifts towards early, aggressive management of the disease. Although guidelines support early use of DMARDs, concomitant use of other drugs, such as NSAIDs, continues at significant levels. Th
Big Pharma Turns to Biologics for Growth to 2010
Big Pharma (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal
Stem Cells 2006
An up-to-date overview and analysis of technology, business, regulatory trends and key company profiles.
Results 1 - 8 of 8
|
